Video

Dr. Carvajal Discusses the Biology of Extracutaneous Melanoma

Richard Carvajal, MD, director of Experimental Therapeutics and director of the Melanoma Service at Columbia University Medical Center, discusses the biology and distinctions of extracutaneous melanoma.

Richard Carvajal, MD, director of Experimental Therapeutics and director of the Melanoma Service at Columbia University Medical Center, discusses the biology and distinctions of extracutaneous melanoma.

Extracutaneous melanoma is a very distinct disease from a biological and clinical standpoint, according to Carvajal. Extracutaneous melanoma needs to be thought of as a different disease than cutaneous melanoma, Carvajal adds, since they do not respond to treatments the same way.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD